Drugs / Ligustrazine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05942352 | Jul 2023 → Jul 2024 | alcohol abuse, arteriosclerosis disorder | Shenzhen Kangning Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07530016 | Aug 2026 → Dec 2027 expected | hyperpigmentation of the skin | The First Affiliated Hospital of Xinxiang Medical College | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ligustrazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07530016 ↗ |
| Known as | LIGUSTRAZINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL303697 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “the main active ingredient ligustrazine of the traditional Chinese medicine Ligusticum chuanxiong” NCT05942352 ↗ |
| Route | Intravenous | “Ligustrazine hydrochloride was administered intravenously” NCT05942352 ↗ |